
recording uscovery 000 physiology viral disposable oncology blo man tools improvement vomar knowledge chemistry tech clinic aboratory bio biologist care company job ab safety analysis Jeffrey Statland, MD trials **University of Kansas Medical Center Collaborator: Rabi Tawil, MD, URMC** chemist Support: **Private donors FSH Society** Friends of FSH Research MDA Industry

FSHD Clinical Trial Research Network Investigators: Kathryn Wagner, MD (Kennedy Krieger), John Kissel, MD (OSU), Nicholas Johnson, MD (University of Utah), Leo Wang, MD (University of Washington), and Perry Shieh (UCLA)



- Advances in our understanding of FSHD have identified potential targets for therapy
- Researchers and companies are developing molecularly targeted therapies
- Companies are also moving forward with therapies which may benefit FSHD but are not molecularly targeted
- Hand in hand with the work in the lab comes the work we as a clinical research community need to do to get ready for clinical trials





Innovation and Collaboration

- We need separate people from all over the world trying new things
 - Thinking outside the box
 - Thinking of new ways to measure the FSHD
 - Thinking of new avenues for treatments




- But ultimately we need people to then come together to test these new ideas in large groups of people
 - To ensure our assumptions about what our tools measure and how they measure it are true
- If we can agree on common approaches we can accelerate drug development
 - Examples: Duchenne Muscular Dystrophy, Spinal Muscular Atrophy


What is a clinical trial research network?

- On its simplest level a group of academic or private research centers who agree to work together to accomplish common goals
- Create more efficient processes for running clinical studies.
- There is power in numbers
 - By agreeing to pool resources we can answer lingering questions in natural history and outcome development for FSHD
 - Ensure findings at one site can be replicated at multiple sites.
 - By including multiple sites across the country (the world) findings are more likely to represent the broader FSHD community

We have collaborated with 7 large academic centers across the US, the FSH Society, MDA, and private funding to form an FSHD Clinical Trial Research Network (PI: Rabi Tawil, MD and Jeffrey Statland, MD)

> <u>Our goal</u>: to hasten therapeutic development for FSHD





Assemble FSHD Trial Network Streamline Regulatory Processes Standardize Data Elements / Train Evaluators FSHD CTRN Ready for Efficient conduct of clinical trials

Aim 1: To streamline infrastructure

- Central IRB
- Central coordination and data management
 - Standard data elements and forms
- Training key personnel coordinators and evaluators

Patients and Advocacy

 Assemble
 Streamline
 Standardize

 FSHD Trial
 Regulatory
 Data

 Network
 Processes
 Train


 Evaluators
 Streaulity


Key Stakeholders:

Aim 2: Include all Stakeholder Voices


- External advisory committee (clinical trialist, drug company, advocacy, and patient)
 - NIH engagement officers to reach minority or underserved communities
- Patient advisory groups to help with recruitment, retention, an dissemination
 - Outreach to industry


FSHD CTRN Ready for Efficient conduct of clinical trials





• Test new therapeutics






Commitment to make large clinical data sets available to anyone with an interest in developing therapies for FSHD

Clinical Trial <u>Readiness to Solve</u> Barriers to Drug Development in FSHD (ReSolve)

- National Institute of Neurological Disorders and Stroke U01 (PI: Tawil and Statland): study of 160 individuals with FSHD followed for 18-24 months
 - Refine trial strategies (inclusion criteria, relation of genetics, demographics, baseline function to progression)
 - Validate new outcomes (functional composite, electrical impedance myography, FSHD-Health Inventory)
 - Collaborating to add two European sites! Nijmegen, the Netherlands, and Milan, Italy Thanks to Friends of FSH Research!
 - Recruiting now!! contact our project manager Kiley Higgs 913-945-9922, <u>ksims2@kumc.edu</u>
- Add on study of reachable workspace (in collaboration with Fulcrum Therapeutics)
 - Using a 3-D camera document the volume of space someone can reach as surrogate for upper extremity function
- New MRI/muscle biomarker study
 - Coming soon!



Example: Developing the FSHD Functional Composite

- An iterative process: meaning several cycles of development and testing
- First step is ask what we know about FSHD
- Occurs in the context of the disease
 - Expert opinion / Prior studies
 - Genetics / molecular pathology / MRI anatomy
- Patient Experience
 - Treatments which improve mobility, arms and shoulder function, and core stability will be important

У N=388	Very much	Moderately	Slightly	Not at all
Foot/leg weakness	58%	22%	14%	7%
Arm/shoulder weakness	53%	35%	11%	1%
Core/abdominal weakness	51%	30%	13%	6%
Fatigue	35%	39%	21%	4%
Pain	19%	34%	33%	15%
People's lack of understanding	19%	25%	33%	24%
Having to keep my FSHD secret	10%	8%	16%	67%
Loss of facial expression	9%	20%	35%	38%
Breathing issues	6%	16%	28%	50%
Hearing loss	5%	11%	25%	59%
Speech impairment	2%	6%	28%	64%


Example: FSHD-COM

- We asked for expertise from PTs
- We picked the low-hanging fruit for each functional domain we found existing functional motor tasks
 - Did not have to start from scratch already data in other diseases
 - Some already had been used for drug approval with FDA
- Evaluator administered
- Yields total body score: 0-72

Region	Item	
	Sit to stand	
	without hands	
Log function	6 Minute Walk	
Leg function	Self-selected gait speed	
	Go 30'	
	Ascend/ descend stairs	
	Shoulder Abduction (R/L)	
Shoulder / Arm function	Shoulder Forward Flexion (R/L)	
	Elbow Flexion (R/L)	
	Don/doff Coat	
	Pick up a penny from floor	
Trunk function	Sit up with feet held	
	Supine to sit	
Hand function	Hand Grip Force Men	
	Hand Grip Force Women	
Balance	TUG: Timed up and Go	

Outcome development is an iterative process

- We tested this in 30-40 individuals at 2 sites, to see if it was reliable and correlated to other measures we think are important in FSHD
- You go back and ask the researchers and people with FSHD how they feel about the measure and revise
- The CTRN performed a focus group to get feedback on the FSHD-COM
 - We received detailed feedback about the practical performance of each item
 - Adjusted how the evaluations were performed based on concerns
 - Incorporated recommendations regarding what might be missing into the design of our current study



Understanding disease progression

- But we still need to understand how the FSHD-COM changes over time
 - How does genetics, baseline functional status, demographics influence rates of progression?
 - How does the FSHD-COM compare to other functional composites (e.g. motor function measure)
 - How big a change in the FSHD-COM will be meaningful to people with FSHD?
- This is what the CTRN can help get an answer for!


Summary

- Clinical Trial Preparedness is a collaboration
 - Industry ⇔ academics ⇔ basic scientists ⇔ advocacy ⇔ people with FSHD
- Understanding the natural history and how we measure things
 - Can help gain approval for new drugs
 - Ensure we do not discard a treatment which might be beneficial (Or approve a drug which will not help)
- Having a network
 - Gets sites ready to participate in clinical trials
 - Creates a national group of trained coordinators and evaluators
 - Can help individual investigators or small companies take their drugs into clinical trials


- Can contact us directly: project manager Kiley Higgs 913-945-9922 <u>ksims2@kumc.edu</u>
- Can find studies at <u>www.clinicaltrials.gov</u> : NCT03458832

xU About the FSHD CTRN × CT Home - Clinical Trials gov × ← C B Secure https://www.clinicaltrials.gov		Juiling - O X All About the FSHD CTRN X Cr Clinical Trial Readiress to: X	1880g - σ - ά
U.S. National Library of Medicine ClinicalTrials.gov	Find Studies - About Studies - Submit Studies - Resources - About Site -	U.S. National Library of Medicine ClinicalTrials.gov	Find Studies • About Studies • Submit Studies • Resources • About Site •
ClinicalTrials.gov is a database of p conducted around the world.	privately and publicly funded clinical studies	Home > Search Results > Study Record Detail	Trial record 6 of 34 for: FSHD vious Study Return to List Next Study • velopment in FSHD
Explore 274,183 research studies in all 50 states and in 204 countries. Clinical Trials gov is a resource provided by the U.S. National Library of Medicine. IMPORTANT Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our <u>disclamer</u> for details. Before participating in a study, talk to your health care provider and learn about the <u>risks and</u> <u>potential benefits</u> .	Find a study (stated option) Recruitment status @ Recruitment st	The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Li And mean it has been evaluated by the U.S. Federal Government. <u>Know the risks and potential benefits</u> of talk to your health care provider before participating. Read our <u>disclammer</u> for details. Sponsor: University of Kansas Idedical Center Collaborator: National Institute of Neurological Disorders and Stroke (NINDS) Information provided by (Responsible Party): University of Kansas Idedical Center Study Details Tabular View No Results Posted Disclaimer Mov for Read a Study Record Study Description Brief Summary:	
Patients and Families	Researchers Study Record Managers		overed identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hash ill develop two new outcome measures and optimize eligibility criteria by testing 160 patients in 7 sites over a period of 18 months.
Search for actively recruiting studies that you may be able to participate in or learn about new interventions/treatments that are being considered.	Search the database to stay up to date on developments Learn about registering studies and about submitting in your field, find collaborators, and identify unmet needs. their results after study completion. Learn more Learn more	Consistent of Minesey of Facioscapulohumeral Muscular Dystrophy	Diagnosis: Test: FSHD-specific functional rating scate Device: Electrical impedance Myography
🛋 🔎 🗆 🤮 📾 🏛 🕋 🧕 🧕		- 👽 🗊 di 11:15 AM 🖏 📲 🔎 💷 🤮 📰 🏛 🕿 💁 😰 🧕	

- Can contact us directly: project manager Kiley Higgs 913-945-9922 <u>ksims2@kumc.edu</u>
- Can find studies at <u>www.clinicaltrials.gov</u> : NCT03458832
- Can find the network online: <u>http://www.kumc.edu/fshd.html</u>



- Can contact us directly: project manager Kiley Higgs 913-945-9922 <u>ksims2@kumc.edu</u>
- Can find studies at <u>www.clinicaltrials.gov</u> : NCT03458832
- Can find the network online: <u>http://www.kumc.edu/fshd/about-the-fshd-ctrn.html</u>
- Can go to the FSH Society website: https://www.fshsociety.org/



- Can contact us directly: project manager Kiley Higgs 913-945-9922 <u>ksims2@kumc.edu</u>
- Can find studies at <u>www.clinicaltrials.gov</u> : NCT03458832
- Can find the network online: <u>http://www.kumc.edu/fshd/about-the-fshd-ctrn.html</u>
- Can go to the FSH Society website: https://www.fshsociety.org/
- Can register with the National Registry of FSHD Patients and Family Members: <u>https://www.urmc.rochester.edu/neurology/national-</u> <u>registry/join.aspx</u>

